EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access · CC BY 4.0

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 – Pharmacokinetic, pharmacogenetic and clinical aspects

Xenia M Hart iD, Gerhard Gründer iD, Christoph Hiemke iD, Ivana Adamovic, Friederike Amann iD, Pierre Baumann iD, Niels Bergemann iD, Christian Brandt, Hans-Willi Clement, Andreas Conca iD, Jürgen Deckert iD, Otto Dietmaier und 38 weitere

Pharmacopsychiatry · 2026-07 · 59 (04) · 166-295

DOI: 10.1055/a-2860-7861 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacopsychiatry, online erschienen am 02.07.2026. Verfasst von Xenia M Hart und 49 weiteren Autor:innen. Beteiligte Einrichtung: Keio University School of Medicine, Department of Neuropsychiatry, Japan, Tokyo. Hauptthemen laut MEDLINE: Drug Monitoring, Pharmacogenetics, Psychopharmacology, Psychotropic Drugs. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 1551 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TDM involves measuring and interpreting drug concentrations in blood plasma or serum to optimize pharmacotherapy. In psychiatry and neurology, TDM is a well-established tool for personalized drug treatments. The AGNP-TDM task force initially published guidelines for best practice TDM in 2004, 2011, and 2017. A fundamental methodological revision has now been carried out on how to determine therapeutic reference ranges and dose-related reference ranges transparently and systematically. In the current edition, 50 experts in neuropsychopharmacology offer a complete update of both ranges for each substance following an evidence-based approach. Various types of data were considered for reference range determination, ranging from meta-analyses to drug concentrations expected under recommended doses. Therapeutic reference ranges are now listed for 160 neuropsychiatric drugs, newly included for 30 drugs and revised for 88 drugs. Expected drug concentrations can be calculated based on a revised formula for 162 drugs. Obligatory TDM (i.e. for dose titration) is strongly recommended for 15 neuropsychiatric drugs and recommended for 39 drugs. TDM is classified as useful for 49 drugs and potentially useful for 62 drugs, indicating that it is recommended in specific clinical situations, such as suspected non-adherence, insufficient clinical response despite recommended doses, relapse during maintenance treatment, and many more. The 2026 update includes practical pharmacogenetic recommendations that are directly relevant to TDM. This work integrates a combination of strategies to guide drug treatments in clinical practice using all available tools. A consistent implementation of TDM and pharmacogenetic recommendations will enhance neuropsychopharmacotherapy, improve patient outcomes, and reduce healthcare costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug MonitoringPharmacogeneticsPsychopharmacologyPsychotropic DrugsPractice Guidelines as TopicHumansConsensus

Substanzen

Psychotropic Drugs

Autor:innen und Institutionen

  • Keio University School of Medicine, Department of Neuropsychiatry, Japan, Tokyo.
  • Medical Faculty Mannheim, University of Heidelberg, Central Institute of Mental Health, Department of Molecular Neuroimaging, BW, Germany, Mannheim.
  • University Hospital Carl Gustav Carus, Technische Universität Dresden, Department of Psychiatry and Psychotherapy, Germany, Dresden.
  • partner site Mannheim - Heidelberg - Ulm, German Center for Mental Health (DZPG), Mannheim, Germany.
  • University Medical Center Mainz, Department of Psychiatry and Psychotherapy, Institute of Clinical Chemistry and Laboratory Medicine, Germany, Mainz.
  • University of Göttingen, Faculty of Medicine, Department of Psychiatry and Psychotherapy, NDS, Germany, Göttingen.

ORCID-Profile: Xenia M Hart, Gerhard Gründer, Christoph Hiemke, Friederike Amann, Pierre Baumann, Niels Bergemann, Andreas Conca, Jürgen Deckert, Karin Egberts, Stefanie Fekete, Ekkehard Haen, Martina Hahn, Stefan Leucht, Andreas Menke, Thomas Messer, Rainald Moessner, Michael Paulzen, Bruno Pfuhlmann, Maike Scherf-Clavel, Markus Schwarz, Julia C Stingl, Gerald Zernig, Georgios Schoretsanitis

Zitieren

APA

Hart, X. M., Gründer, G., Hiemke, C., Adamovic, I., Amann, F., Baumann, P., Bergemann, N., Brandt, C., Clement, H. W., Conca, A., Deckert, J., Dietmaier, O., Eckermann, G., Egberts, K., Endres, K., Erlacher, N., Fekete, S., Ferrea, S., Florio, V., …, & Schoretsanitis, G. (2026). Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 – Pharmacokinetic, pharmacogenetic and clinical aspects. Pharmacopsychiatry, 59(04), 166-295. https://doi.org/10.1055/a-2860-7861

Vancouver

Hart XM, Gründer G, Hiemke C, Adamovic I, Amann F, Baumann P, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 – Pharmacokinetic, pharmacogenetic and clinical aspects. Pharmacopsychiatry. 2026;59(04):166-295. doi:10.1055/a-2860-7861

BibTeX
@article{Hart2026,
  author = {Hart, Xenia M and Gründer, Gerhard and Hiemke, Christoph and Adamovic, Ivana and Amann, Friederike and Baumann, Pierre and Bergemann, Niels and Brandt, Christian and Clement, Hans-Willi and Conca, Andreas and Deckert, Jürgen and Dietmaier, Otto and Eckermann, Gabriel and Egberts, Karin and Endres, Katharina and Erlacher, Nicole and Fekete, Stefanie and Ferrea, Stefano and Florio, Vincenzo and Gerlach, Manfred and Haen, Ekkehard and Hahn, Martina and Havemann-Reinecke, Ursula and Hefner, Gudrun and Jost, Wolfgang H and Kuzin, Maxim and Laux, Gerd and Leucht, Stefan and Maniscalco, Ignazio and Menke, Andreas and Messer, Thomas and Moessner, Rainald and Müller, Daniel J and Müller, Thomas and Paulzen, Michael and Petri, Holger and Pfeifer, Philippe and Pfuhlmann, Bruno and Riederer, Peter and Roll, Sibylle C and Scherf-Clavel, Maike and Schwarz, Markus and Steimer, Werner and Stingl, Julia C and Toto, Sermin and Ulrich, Sven and Zernig, Gerald and Zurek, Gabriela and Unterecker, Stefan and Schoretsanitis, Georgios},
  title = {Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 – Pharmacokinetic, pharmacogenetic and clinical aspects},
  journal = {Pharmacopsychiatry},
  year = {2026},
  volume = {59},
  number = {04},
  pages = {166--295},
  doi = {10.1055/a-2860-7861}
}
Kostenlos starten →